Lamifen

Quick links to important sections

Lamifen

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lamifen

Quick Facts

Property Description
Active ingredient Terbinafine Hydrochloride
Form Oral tablet, Topical cream/solution
Pharmacological class Allylamine Antifungal
General purpose Eliminating fungal infections
Origin Synthetic compound

What Type of Medicine is Lamifen (Terbinafine Hydrochloride)?

Lamifen is a medication defined by its core active component, Terbinafine Hydrochloride (INN). This drug is classified as a synthetic allylamine antifungal agent, belonging to the larger family of antifungal medications. As a single-ingredient product, it is manufactured to achieve a highly targeted effect against pathogenic fungi. The classification as an allylamine is significant, as it indicates a unique and potent mechanism of action against these organisms.


Lamifen: Available Forms and General Therapeutic Purpose

Lamifen is available in two distinct types: an oral tablet for systemic use and various topical forms (such as a cream or solution) for local application. The general therapeutic purpose of this medication is the effective elimination of fungal pathogens, specifically those known as dermatophytes. The oral tablet form is frequently indicated for fungal infections because the systemic delivery allows the drug to reach deep-seated sites, such as the nails. This flexibility ensures that the appropriate form can be used depending on the infection's location and severity.


Core Antifungal Action

The active ingredient, Terbinafine, is characterized by its powerful fungicidal action, which means it actively kills the fungal organism rather than merely slowing its growth. This effect is achieved through high selectivity, targeting essential metabolic processes unique to the fungal cell. This fungicidal property is clinically recognized for its high specificity against the fungal enzyme squalene epoxidase, and it provides the foundational benefit for patients: leading directly to the eradication of the pathogen, which is crucial for achieving a permanent resolution of the infection.

Regulatory References

  1. NIH DailyMed for Terbinafine Hydrochloride Tablets

What side effects are possible with Lamifen?

Possible Side Effects and Safety Information

The officially documented safety profile for Lamifen (Terbinafine Hydrochloride) is structured around effects categorized by frequency and the body's physiological systems involved, as established in government regulatory documents.

Adverse Reaction Classification

The most common adverse reactions reported in clinical data include headache, diarrhea, rash, dyspepsia (indigestion), and nausea. Other common effects include pruritus (itching) and disturbances in taste or smell.

Reactions categorized as rare or very rare by regulatory authorities include severe effects on the body. These may involve the Hepatobiliary System, such as cases of liver enzyme elevation or, rarely, liver failure, which has been documented in individuals both with and without pre-existing liver disease. Effects on the Blood and Lymphatic System have included reports of severe neutropenia and pancytopenia.

Serious Safety Considerations

Official prescribing information documents the potential for serious cutaneous adverse reactions, including life-threatening conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The precipitation or exacerbation of Lupus Erythematosus is also a documented safety element.

Population-Specific Safety Restrictions

Regulatory documents establish specific constraints for use in certain populations. The oral form is officially not recommended or contraindicated in individuals with active or chronic liver disease. Additionally, use is generally not recommended in patients with severe renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Lamifen (Terbinafine Hydrochloride) outlines specific manifestations and required actions in the event of an overdose.

Documented Overdose Manifestations

Following an acute oral overdose, the most commonly documented clinical presentations involve disturbances to the gastrointestinal (GI) and central nervous systems (CNS). These manifestations officially include headache, dizziness, nausea, vomiting, and stomach pain (epigastric pain). Other listed signs may include rash and frequent urination.

Required Emergency Actions

Regulatory authorities mandate that immediate medical attention be sought for any known or suspected overdose. Patients are instructed to contact emergency services or a poison control center for urgent clinical evaluation and management.

Official Management and Considerations

In the absence of a known specific antidote, the official management of overdose focuses on procedural supportive care. Procedures described in the regulatory texts include the administration of activated charcoal to aid in the elimination of the active substance, alongside necessary symptomatic and supportive therapy. Regarding formulation, overdose of the topical cream is considered extremely unlikely due to its minimal systemic absorption. Accidental ingestion of the topical product is expected to result in exposures comparable to a single therapeutic oral dose, leading to similar reported adverse effects.

Therapeutic Uses of Lamifen

Lamifen is used for managing symptomatic conditions related to specific fungal infections, and may assist with easing associated discomfort and functional strain. Clinical contexts for its use include situations involving fungal infections of the nails and skin.

Managing Acute Symptom Burdens and Intensity

Lamifen is commonly used in situations involving symptoms related to physical discomfort and heightened patient distress. It is relevant in conditions presenting with systemic or localized discomfort. Lamifen is applied in addressing symptom clusters that may become intense or disruptive, providing support that helps ease the overall symptom burden during acute episodes.

Support for Distressing Symptom Manifestations

The medication is applied in clinical settings where symptoms create noticeable interference with daily stability. Lamifen is commonly used across conditions presenting with episodic or fluctuating symptom patterns.

“It helps address symptoms that interfere with daily comfort, supporting patients during episodes of heightened discomfort.”

This focus on relief contributes to comfort during symptomatic periods and supports functional stability.


Quick Fact: Support during Functional Strain Lamifen is often applied during phases where the patient experiences heightened discomfort or temporary functional strain, and may assist with general symptomatic management.


Relief During Periods of Functional Strain

Used across domains where short-term symptomatic assistance is appropriate, Lamifen is considered relevant in contexts involving heightened systemic burden. The medication offers symptomatic relief that may help patients cope more steadily with difficult manifestations, and is helpful in situations requiring additional symptomatic assistance.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Lamifen (Terbinafine oral tablets) eligibility is defined by official regulatory documentation, primarily around contraindications and conditional use based on specific patient populations and health status.

Contraindications and Restrictions

Category Regulatory Status Constraint
Absolute Prohibition Contraindicated Individuals with Chronic or Active Liver Disease or a history of allergic reaction to terbinafine must not use this medicine.
Renal Impairment Use Not Recommended Not recommended in patients with severe renal impairment (Creatinine Clearance < 50 mL/min) due to insufficient study data and decreased drug clearance.
Pregnancy/Lactation Use Not Recommended Not generally recommended during pregnancy (limited human data) or while breastfeeding (excreted into human milk).
Pediatric Use Not Established Safety and efficacy have not been established for treating onychomycosis in the pediatric population (children under 18).
Conditional Use Caution Required Use requires caution in patients with pre-existing conditions like Systemic Lupus Erythematosus (SLE) or immunodeficiency.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Lamifen (Terbinafine Hydrochloride) around its significant pharmacokinetic effects on metabolic enzymes, primarily the Cytochrome P450 (CYP) system. The drug is formally documented as a potent inhibitor of the CYP4502D6 isozyme. This inhibitory action may lead to an increase in the plasma concentration of co-administered medicines that are predominantly metabolized by CYP2D6, such as certain antidepressants and beta-blockers (e.g., desipramine, metoprolol).

Conversely, the clearance of Lamifen itself is significantly altered by medicines that influence CYP enzyme activity.

Substance Type Example Medicine Official Interaction Outcome
Enzyme Inhibitor Cimetidine, Fluconazole Decreased clearance of terbinafine; increased exposure (e.g., Fluconazole increased AUC by 69%).
Enzyme Inducer Rifampicin Increased clearance of terbinafine by 100%; reduced systemic exposure.

Pharmacodynamic interactions have been reported in rare post-marketing cases with Warfarin, where changes in INR and/or prothrombin time were observed. Regarding non-medicinal substances, Lamifen formally decreases the clearance of caffeine. Furthermore, the evaluation of potential interactions must account for population-specific constraints, as Lamifen is not recommended for use in patients with chronic or active liver disease due to reduced clearance.

Mechanism of Action

Targeted Fungal Enzyme Inhibition and Cell Lysis

Lamifen, containing Terbinafine, exerts a highly selective mechanism by targeting the fungal enzyme Squalene Epoxidase (SE). The drug acts as a non-competitive inhibitor of SE, effectively blocking the conversion of squalene to lanosterol, which is a critical step in the fungal cell's sterol biosynthesis pathway.

This blockade triggers a dual mechanistic cascade resulting in fungal cellular destruction. Firstly, the pathway disruption causes a significant deficiency of ergosterol, compromising the structural integrity of the fungal cell membrane. Secondly, the enzyme's substrate, squalene, accumulates to toxic concentrations inside the fungal cell, resulting in chemical damage. This dual action leads to the physical destruction (lysis) of the fungal cell.

The drug is highly keratophilic, a characteristic that facilitates its rapid and persistent partitioning into keratinous tissues, such as the skin, nails, and hair. This mechanical affinity establishes a local tissue reservoir, ensuring that inhibitory concentrations are maintained at the fungal proliferation site for an extended duration.

Dosage and Administration Information

Lamifen (terbinafine) is administered through distinct routes depending on the clinical context: oral for systemic treatment, and topical for localized dermatologic application. The medication follows a standardized administration protocol detailed in established documentation.

Element Detail
Route of Administration Oral (Tablet, Granule) or Topical (Cream/Solution).
Standard Adult Dose 250 mg daily for approved indications.
Frequency Pattern Administered once daily for all official oral regimens.

Oral tablet administration may occur with or without food. However, the oral granule form requires specific administration conditions: it must be mixed with a spoonful of soft, non-acidic food, such as mashed potatoes, and swallowed immediately without chewing. The use of fruit-based or acidic foods is specified as unsuitable for granule intake.

The total duration of therapy is defined by the specific infection; for instance, treatment for toenail onychomycosis is typically prescribed for 12 weeks, while fingernail onychomycosis requires a 6-week course. Specific weight-based dose tiers are applied when the oral granule form is used in pediatric patients, ranging from 125 mg to 250 mg daily based on body weight. Prior to initiating oral therapy, evaluation of existing liver function is part of the standardized use protocol.

In the event of a missed dose, the standard instruction is to take it when remembered, unless the time is close to the next scheduled dose, in which case the missed dose should be skipped to prevent taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lamifen

The clinical evidence for Lamifen (Terbinafine) has been evaluated through formal scientific research, including controlled trials and comprehensive reviews. The research primarily describes studies evaluating outcomes related to specific fungal infections of the nails and skin.

Evidence for Use in Fungal Nail Infections (Onychomycosis)

Research into the systemic (oral tablet) form of Lamifen for fungal nail infections has largely relied on Randomized Controlled Trials (RCTs) and pooled data analyses. Researchers aimed to measure two key endpoints: the rate of mycological endpoints, which is measured by laboratory tests for the presence of the fungus, and the clinical status, which involves observing changes in the appearance of the nail. Studies monitored the patients for an extended period, often from 12 to 18 months, following the conclusion of the treatment phase to observe the durability of the effect. Studies indicated that because of the time required for nail regrowth, observation periods extending over a year were needed to gather full outcome measurements.

Evidence for Use in Common Skin Fungal Infections

The research exploring the topical forms of Lamifen, such as creams and solutions, for conditions like Athlete's Foot (tinea pedis) has also used controlled study designs, typically vehicle-controlled trials. Studies monitored patient-reported outcomes describing perceived discomfort, such as itching and burning, as well as visual assessments like scaling and redness. Follow-up for these studies is generally shorter, with observation periods typically extending for several weeks post-treatment to confirm that the status was sustained.

Research Gaps and Evidence in Specific Populations

Research has been conducted, but there are areas where data remain limited. Evidence is limited for specific uses of Lamifen in certain patient groups, such as children and older adults, as many pivotal studies focused predominantly on the adult population. Additionally, certain evidence quality varies across studies, and data for specific types of severe or extensive infections remain insufficient. The research does not determine whether an individual will respond similarly; study results reflect the specific conditions and populations under which they were conducted.

Key Studies & References

  1. Efficacy and Safety of Terbinafine 1% Solution in the Treatment of Interdigital Tinea Pedis and Tinea Corporis or Tinea Cruris
  2. Terbinafine - StatPearls (NIH): Review of Indications and Evidence Level

Frequently Asked Questions (FAQ)

Common questions about Lamifen (FAQ)

Q: How quickly does Lamifen typically start to work for skin infections?

For topical forms of Lamifen used on skin infections like athlete’s foot, official information indicates that relief of symptoms is typically experienced within a few days. If no improvement is observed after two weeks, it is important to seek further advice from a healthcare professional.


Q: What are the most common reasons doctors prescribe Lamifen?

Lamifen oral tablets are officially approved for treating fungal infections of the fingernails and toenails, known as onychomycosis. The topical creams and solutions are approved for treating common skin fungal infections like athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis).


Q: What medications should definitely not be taken with Lamifen?

Regulatory documents highlight that Lamifen is a potent inhibitor of the CYP2D6 enzyme. This means it can potentially increase the level of many other medicines in the bloodstream, including certain antidepressants and beta-blockers. Additionally, taking it with strong enzyme inducers, such as rifampicin, is not recommended as it reduces Lamifen's effectiveness.


Q: Can Lamifen cause hair loss?

According to official safety data, hair loss, or alopecia, has been reported as a very rare or post-marketing adverse reaction associated with the use of Lamifen oral tablets.


Q: Are there any long-term side effects associated with Lamifen use?

The drug has a very long terminal half-life, meaning it is eliminated very slowly from body tissues like the skin and fat. While official information lists various reported side effects, there is no distinct category of 'long-term' side effects formally defined in the regulatory documents.


Q: Does alcohol interact negatively with Lamifen?

Official warnings state that oral Lamifen is contraindicated in patients with chronic or active liver disease. Given that Lamifen is contraindicated in those with liver disease, any factors, such as alcohol, that may affect liver function warrant a discussion with a healthcare provider.


Q: Is Lamifen safe for children to use?

Official product information notes that safety and efficacy for treating fungal nail infections have not been established in children under 18. While oral granules are sometimes used for other fungal infections in children aged four and older, use in younger children is not established.


Q: Can Lamifen be used for yeast infections?

Yes, in many regions, the topical forms of Lamifen are officially approved for treating cutaneous candidiasis, which is a common yeast infection of the skin caused by Candida species.


Q: Why do some people take Lamifen for a long time?

Oral Lamifen is typically prescribed for an extended duration, such as 6 to 12 weeks, because of the infection's location. The drug must build up and be delivered to slowly growing keratinous tissues like the nails to effectively treat the fungus.


Q: What are the signs that Lamifen is actually working?

For skin infections, signs of improvement typically include relief from symptoms like itching, burning, and scaling within a few days. For nail infections, it may take several months to see clear signs of new, healthy nail growth due to the slow rate at which nails grow.


Q: Does sun exposure make side effects of Lamifen worse?

Yes, the official label warns that Lamifen tablets can make the skin sensitive to light, leading to reactions like rashes or severe sunburns (photosensitivity). Official information indicates that minimizing exposure to natural and artificial sunlight is generally recommended while the patient is taking the medication.


Q: How long does Lamifen stay in your system?

Lamifen has a complex elimination profile. The drug’s effective half-life in the bloodstream is about 36 hours. However, it is eliminated very slowly from body tissues like the skin and fat, where the terminal half-life is documented as being between 200 and 400 hours.


Q: Is there a generic version of Lamifen available?

Yes. Lamifen's active ingredient, terbinafine hydrochloride, is a well-established medication that is widely available in generic tablet and topical forms.


Q: What does the research say about the effectiveness of Lamifen?

Clinical trials for oral Lamifen in nail infections measured both the eradication of the fungus (mycological cure) and the appearance of a clear nail (clinical cure), confirming its effectiveness against the types of fungi it is intended to treat. Topical studies have confirmed its efficacy against common skin fungal infections.


Q: Can elderly patients use Lamifen safely?

Official information indicates that studies have not identified specific geriatric-related problems. However, general caution may be appropriate because older patients are more likely to have pre-existing conditions, such as kidney or liver impairment, which can affect how the body clears the drug.


Q: Does Lamifen have a reputation for causing drug interactions?

Yes. Regulatory information highlights that Lamifen has a significant potential for drug interactions because it is a potent inhibitor of the CYP2D6 enzyme, which is critical for the metabolism of many other commonly prescribed medications.


Q: Can using too much Lamifen cream cause problems?

Topical Lamifen is intended for external use only. Using the cream only in the prescribed amount is generally recommended. Inadvertent ingestion of large amounts could potentially lead to side effects similar to an overdose of the tablets, such as headache, nausea, and dizziness.


Q: Why do some people experience dry skin with Lamifen cream?

Dry skin, along with skin exfoliation and mild irritation at the application site, are documented as local adverse reactions. These effects are classified as uncommon or rare reactions associated with the use of the topical cream.


Q: Is Lamifen considered a strong antifungal medicine?

Yes, Lamifen is classified as a synthetic allylamine antifungal. It is known for its fungicidal action, meaning it actively kills the fungal organism rather than just slowing its growth, which is considered a powerful effect against dermatophytes.


Q: Are there published studies showing the safety profile of Lamifen?

The safety profile of the drug is formally documented based on data collected from pre-marketing clinical trials, post-marketing surveillance, and spontaneous reporting. This information is summarized in the official regulatory documents.


Q: Is Lamifen an over-the-counter medicine in some countries?

The oral tablet form of Lamifen is prescription-only worldwide. However, the topical cream and spray forms of the active ingredient (terbinafine) are commonly available over-the-counter in many countries for treating skin fungal infections.


Q: What should I do if my symptoms worsen after starting Lamifen?

In the event that symptoms worsen or a new serious reaction occurs—such as signs of liver problems (jaundice) or a severe allergic reaction—the official recommendation is to discontinue the medication and immediately contact a healthcare professional.


Q: Are there specific food restrictions while taking oral Lamifen?

Lamifen tablets can be taken with or without food. However, the oral granule form has specific administration conditions: it must be mixed with a small amount of soft, non-acidic food and swallowed right away.


Q: Is it normal to feel a burning sensation when applying Lamifen cream?

Local symptoms at the application site, including a burning sensation, pain, and irritation, are documented in official information as uncommon adverse reactions following the application of Lamifen cream.


Q: Can Lamifen be used to treat athlete's foot?

Yes, the topical cream and solution forms of Lamifen are formally indicated for the treatment of Athlete’s Foot (tinea pedis). The oral tablets may also be used for certain severe skin fungal infections that do not respond to topical treatment.


Q: What happens if Lamifen cream gets into your eyes?

Topical Lamifen is for external use only. Official patient information notes that if the cream accidentally comes into contact with the eyes, it may cause irritation, and the eyes should be rinsed thoroughly with water.

How should Lamifen be stored and disposed of?

How to Store and Dispose of Lamifen (Terbinafine)

Lamifen (terbinafine hydrochloride) must be stored according to officially documented conditions to maintain stability.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20^circ to 25 C / 68^circ to 77 F). Temporary excursions up to 30 C are permitted.
Protection Must be protected from light and stored away from excessive heat and moisture.
Container Keep in a tight container and store in the original package.
Child Safety Must be kept out of the sight and reach of children.

Official Disposal Instructions

Disposal should follow governmental guidelines for non-flushable medicines. Unused or expired Lamifen should be discarded via a drug take-back program or the officially recommended household trash method (mixed with an undesirable substance in a sealed container). All disposal must be carried out in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lamifen found in:

A-Z Index: